USE OF SPARINGLY SOLUBLE SALTS TO PREPARE ORAL SUSTAINED-RELEASE SUSPENSIONS

被引:15
|
作者
SHAH, KP [1 ]
CHAFETZ, L [1 ]
机构
[1] UNIV MISSOURI,SCH PHARM,CTR PHARMACEUT TECHNOL,KANSAS CITY,MO 64110
关键词
SPARINGLY SOLUBLE SALT; DILTIAZEM; PECTIC ACID; SOLVENT EVAPORATION PROCESS; MICROCAPSULES; SUSTAINED RELEASE; SUSPENSION;
D O I
10.1016/0378-5173(94)90389-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The feasibility of preparing oral sustained release suspensions by using sparingly soluble salts of soluble ionic drugs was assessed in this study. Diltiazem was used as a model drug. A less soluble pectate salt of the drug was prepared and encapsulated by a solvent evaporation process. Cellulose acetate butyrate (CAB) was used as the coating polymer. Percent drug release from CAB microcapsules was modified by using hydrophilic polymers and varying microcapsule drug load. The release was independent of pH and ionic strength of the dissolution medium, an advantage over the existing ion-exchange resin approach. The release profiles fitted a bi-exponential equation, suggesting a biphasic release mechanism; an initial burst effect was obtained followed by slow diffusion of drug through the polymeric coat. Suspensions of diltiazem pectate-loaded microcapsules were prepared in a preserved medium containing sorbitol, syrup, and methylcellulose. Redispersibility of suspensions was satisfactory at room temperature and 4 degrees C, but poor at 37 degrees C. The suspended microcapsules resulted in 8-12% increase in drug release after 1 week storage at room temperature compared to dry microcapsules; however, the release did not increase any further upon extended storage. The suspensions were unstable at 37 degrees C, but remained relatively stable at or below room temperature for up to 26 weeks.
引用
收藏
页码:271 / 281
页数:11
相关论文
共 50 条
  • [31] SUSTAINED-RELEASE ORAL METHYLPREDNISOLONE IN DERMATOLOGY - A CLINICAL EVALUATION
    LUBOWE, II
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1962, 4 (03): : 111 - &
  • [32] Oral sustained-release cisplatin preparation for rats and mice
    Nakano, K
    Ike, O
    Wada, H
    Hitomi, S
    Amano, Y
    Ogita, I
    Nakai, N
    Takada, K
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (05) : 485 - 490
  • [33] ORAL SUSTAINED-RELEASE DRUG DELIVERY - PELLETS OR TABLETS
    SAM, T
    RUBINSTEIN, MH
    PHARMACY INTERNATIONAL, 1985, 6 (11): : 265 - 266
  • [34] SUSTAINED-RELEASE CHLORHEXIDINE PREPARATIONS FOR TOPICAL USE
    FRIEDMAN, M
    GOLOMB, G
    BRAYER, L
    HILLER, C
    JOURNAL OF DENTAL RESEARCH, 1980, 59 : 905 - 905
  • [35] EVALUATION OF A SUSTAINED-RELEASE ORAL TETRACYCLINE IN NONSPECIFIC URETHRITIS
    PERERA, PM
    BRITISH JOURNAL OF VENEREAL DISEASES, 1975, 51 (05): : 333 - 335
  • [36] EVALUATION OF A SOLUBLE SUSTAINED-RELEASE OPHTHALMIC DELIVERY UNIT IN THE DOG
    GELATT, KN
    GUM, GG
    WILLIAMS, LW
    PEIFFER, RL
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 1979, 40 (05) : 702 - 704
  • [37] STUDY OF RELEASE MECHANISM AND BIOAVAILABILITY OF THEOPHYLLINE AND ACETAMINOPHEN FROM NEWLY DESIGNED SUSTAINED-RELEASE SUSPENSIONS
    KAWANO, H
    NAKAZONO, N
    INOTSUME, N
    NAKANO, M
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (11) : S275 - S275
  • [38] ORAL SUSTAINED-RELEASE RITODRINE AS A SUBSTITUTE FOR PROLONGED INTRAVENOUS TOCOLYSIS
    GEMER, O
    SASSOON, E
    SEGAL, S
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1994, 55 (02): : 109 - 110
  • [39] COMPARATIVE BIOAVAILABILITY OF 2 ORAL SUSTAINED-RELEASE PROCAINAMIDE PRODUCTS
    BAKER, BA
    REYNOLDS, JR
    GLECKEL, L
    AZARY, E
    BODENHEIMER, MM
    CLINICAL PHARMACY, 1988, 7 (02): : 135 - 138
  • [40] EFFECT OF METOCLOPRAMIDE ON THE ABSORPTION OF AN ORAL SUSTAINED-RELEASE QUINIDINE PRODUCT
    YUEN, GJ
    HANSTEN, PD
    COLLINS, J
    CLINICAL PHARMACY, 1987, 6 (09): : 722 - 725